Fact CheckerSign in

NCT07668349Recruiting

Effects of Modified Constraint-Induced Movement Therapy and Mirror Therapy in Hemiplegic Stroke

Comparison of the Effects of Modified Constraint-Induced Movement Therapy and Mirror Therapy Applied to the Upper Extremity on Motor Function, Participation, and Independence in Activities of Daily Living in Hemiplegic Stroke Patients: A Randomized Controlled Trial

Source: ClinicalTrials.gov · Last updated 25 Jun 2026

Brief summary (registry, in English)

The purpose of this study is to investigate and compare the effects of Modified Constraint-Induced Movement Therapy (mCIMT) and Mirror Therapy (MT) on upper extremity motor functions, activity participation, and independence in daily living activities among hemiplegic stroke patients. Participants diagnosed with stroke will be randomly assigned to intervention groups. The study aims to determine which therapeutic modality provides a higher contribution to the functional recovery of the paretic upper limb and overall quality of life.

Status (registry)
Recruiting
Study type
Interventional
Enrollment
16 (estimated)
First submitted
19 Jun 2026
Start date
Feb 2026
Primary completion date
Sept 2026
Lead sponsor
Nisa Kiliç Koçak
Diseases
Stroke
NCT number
NCT07668349

What you commit to

  • Study type: Interventional
  • Planned participants: 16
  • From Feb 2026 to the primary completion date, Sept 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • \* Uncontrolled diabetes or other metabolic disorders.
    • Progressive non-stroke neurological diseases (e.g., Parkinson's disease, multiple sclerosis).
    • Terminal illness or short life expectancy.
    • Severe cognitive impairment preventing comprehension or execution of the study protocols (e.g., advanced dementia).
    • Severe visual impairment that prevents mirror therapy application (e.g., uncorrected visual acuity loss, neglect).
    • Severe visuospatial perception disorders making it difficult to perceive or interpret the mirror image.
    • Absence or minimal level of active movement in the affected upper extremity (limiting the applicability of modified CIMT).
    • Significant motor deficit in the unaffected upper extremity.
    • Severe and uncontrolled spasticity in the upper extremity.

Who the study is looking for

  • \* Diagnosis: Confirmed first ischemic or hemorrhagic stroke with clinical and neurological evaluation.
    • Time Since Stroke: 3 to 24 months post-stroke onset.
    • Hemiplegia: Significant motor deficit in the affected upper extremity.
    • Motor Function Level: Presence of mild to moderate motor impairment in the affected upper extremity (FMA-UE score appropriate for the application of modified CIMT and mirror therapy).
    • Cognitive Status: Adequate cognitive capacity to understand and follow the study protocols (Mini-Mental State Examination score of 20 or above).
    • Visual Perception: Adequate visual perception to perform mirror therapy.
    • Comorbidities: Absence of severe coexisting medical conditions that prevent participation (e.g., uncontrolled cardiovascular diseases, severe psychiatric disorders).
    • Prior Treatments: No prior intensive participation in the interventions investigated in this study (modified CIMT or mirror therapy).
    • Consent: Voluntary agreement to participate and signed informed consent form.

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Akay Special Education and Rehabilitation Center
Coordinator of this site? Confirm its status
KastamonuTurkey (Türkiye)Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.